Key facts
- This page summarizes Srinivas Rao's Form 4 filing for AtaiBeckley Inc. (ATAI).
- 11 reported transactions and 9 derivative rows are listed below.
- Accepted by SEC: 11 Sep 2026, 17:44.
Srinivas Rao - 11 Sep 2026 Form 4 Insider Report for AtaiBeckley Inc. (ATAI)
- Reporting relationship
- Co-Founder and Chief Executive Officer, Director
- Issuer ticker
- ATAI
- Reported as of
- 11 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Sep 2026, 17:44:16 UTC
- Prior SEC filing
- 03 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Barrett, as attorney in fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Srinivas Rao filed Form 4 for AtaiBeckley Inc. (ATAI) on 11 Sep 2026.
Change
- Previous filing in this sequence was filed on 03 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001860902
Primary reporting owner
Rao Srinivas
- Relationship
- Co-Founder and Chief Executive Officer, Director
- Address
- C/O ATAI LIFE SCIENCES US, INC., C/O INDUSTRIOUS NYC, 250 WEST 34TH ST., NEW YORK
- Signature
- /s/ Ryan Barrett, as attorney in fact
- Signature date
- 11 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATAI
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -212,942
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F2
ATAI
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -3,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- By Spouse
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -650,795
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 650,795
- Exercise price
- $5.68
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -217,778
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 217,778
- Exercise price
- $2.50
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -2,147,408
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,147,408
- Exercise price
- $2.44
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -777,400
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 777,400
- Exercise price
- $5.65
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -600,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 600,000
- Exercise price
- $1.18
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -800,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800,000
- Exercise price
- $1.84
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -2,340,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,340,000
- Exercise price
- $1.75
- Footnotes
- F3
ATAI
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- Shares
- -1,988,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,988,000
- Exercise price
- $3.76
- Footnotes
- F3
ATAI
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -442,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 442,000
- Exercise price
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Srinivas Rao is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
Footnote F2
At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
Footnote F3
At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Footnote F4
At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting).
SEC remarks
Co-Founder and Chief Executive Officer